BioSight
Companies
Compass Therapeutics, Inc. logo

CMPX

NASDAQBOSTON, MA
Compass Therapeutics, Inc.

Compass Therapeutics is a clinical-stage oncology biopharmaceutical company developing monoclonal antibodies and bispecific antibodies that target angiogenesis and immune pathways in the tumor microenvironment. The company's lead program, tovecimig, is a bispecific antibody targeting DLL4 and VEGF-A currently in Phase 2/3 development for biliary tract cancer in combination with paclitaxel, with additional Phase 2 studies underway in colorectal cancer and planned expansion into ovarian cancer, gastric cancer, renal cell carcinoma, and hepatocellular carcinoma. The pipeline also includes CTX-471, an agonistic antibody targeting CD137 (4-1BB) in Phase 2 development for NCAM-positive tumors; CTX-8371, a bispecific PD-1/PD-

Price history not yet available for CMPX.

Pipeline

No pipeline data on record yet.

Catalyst Calendar

No catalyst events on record for yet. Check back after the next daily ingest.

Disclaimer·BioSight aggregates publicly available data (SEC EDGAR, ClinicalTrials.gov, FDA, company press releases) and is provided as is for informational purposes only. Nothing here is investment, financial, legal, tax, or medical advice, or an offer to buy or sell any security. We make no warranty as to accuracy, completeness, or timeliness; dates and filings may contain errors or be superseded without notice; past events do not predict future outcomes. To the maximum extent permitted by law, BioSight, its operators, contributors, and affiliates disclaim all liability for any loss or damage arising from use of or reliance on this site. You are solely responsible for your own investment decisions — consult a licensed professional before acting on any information.

Unlock 12-month calendar